Introduction
Mutations of p53 tumor suppressor gene are the most common genetic alterations observed in human cancers (1) . It has been demonstrated that the re-expression of wild-type p53 in cancer cells, in which the endogenous p53 gene is deleted or mutated, restores a non-tumorigenic phenotype by suppressing tumor growth and inducing apoptosis (2, 3) . The clinical trial of p53 gene transfer to tumors is effective in ~60% of patients (4) . Nonetheless, several cancers are refractory to the apoptosis induction by p53 gene transfer (5) . Therefore, it is much anticipated to find effective drugs for enhancing the cytotoxicity of p53 gene transfer, and presently radiotherapy and chemotherapy are clinically used in place of those drugs (6) (7) (8) (9) .
Trichostatin A (TSA), which has originally been identified as an anti-fungal drug (10) , inhibits histone deacetylase activity. A number of reports demonstrated that TSA functioned as a specific inhibitor of the mammalian cell cycle and induced apoptotic cell death in a leukemia cell line and several colorectal carcinoma cell lines (11) (12) (13) . Histone acetylation mediates transcription by facilitating the binding of transcription factors to nucleosomal DNA (14) , which suggests that a histone deacetylase inhibitor could promote p53-dependent transcription of down-stream genes such as Bax and p21 waf1/Cip1 and then induce apoptosis more efficiently in combination with p53 gene transfer than p53 gene transfer alone. In fact, one of the histone deacetylase inhibitors has been reported to activate the p21 waf1/Cip1 promoter (17) . Furthermore, recent reports demonstrated that some histone deacetylase inhibitors could synergistically induce apoptosis in combination with p53 gene therapy, compared with p53 gene therapy alone (16) .
In this study, we examined the effects of TSA in combination with p53 gene therapy on the induction of apoptosis in breast cancer cell line MDA-MB-231 and found that TSA treatment synergistically increased the apoptosis induced by p53 gene transfer in MDA-MB-231 cells. in the absence or presence of TSA (0, 250 and 500 nM). After incubation for 48 h, the plates were again incubated for 3 h after an addition of 20 μl of MTS solution. Subsequently, the absorbance was measured at 490 nm with an ELIZA reader (Bio-Rad Model 550). To quantify the cell numbers, a standard curve was created by plating non-treated cells in triplicate wells at the following concentrations: 0, 2,000, 10,000, 20,000 and 50,000 cells/well.
Materials and methods

Cell
Apoptosis was evaluated by FACS analysis using propidium iodide (PI) and Annexin-V-FITC (Boehringer Mannheim, Mannheim, Germany) staining according to the manufacturer's instruction. The cells were placed in the well of 6-well plates (2x10 5 cells/well) and infected with adenovirus vectors (MOI 25-100) in the absence or presence of TSA (250-500 nM). After 48 h post-infection, the cells were collected, washed twice with cold phosphatebuffered saline, and resuspended in 100 μl of binding buffer containing 20 μg/ml PI and 20 μg/ml Annexin-V-FITC. After 15 min, 400 μl of the binding buffer was added and FACS analysis was performed on FACScaliber flow cytometer (Becton-Dickinson, Mountain View, CA). Data analysis was done with CellQuest software. Apoptosis was also investigated by TUNEL staining with the use of an In Situ Cell Detection kit (Rosche Molecular Biochemicals, Manheim) according to the manufacturer's instruction.
Mitochondrial membrane potential and caspase activity. For evaluation of mitochondrial membrane potential, the cells (5x10 5 /ml) were incubated with chloromethyl Xarosamine (CMXRos) (Molecular Probes Inc., Eugene, OR) according to the method described by Macho et al (18) . CMXRos (1 mM) was prepared as a stock solution in dimethylsulfoxide (DMSO) and stored at -20˚C. Caspase activity was evaluated with a CasPACE TM Assay System kit (Promega) according to the manufacturer's instruction.
Northern blot analysis. Northern blot analysis was performed by the method described previously (19) . Total RNA (20 μg) was separated by electrophoresis in 1.2% denaturing formaldehyde-agarose gels. The RNA was transferred to nylon membrane (Hybond N + , Amersham) overnight by capillary elution and UV cross-linked. After pre-hybridization of the blots for 1-2 h at 42˚C in hybridization buffer, the membrane was hybridized overnight at 42˚C with the cDNA probes for p53, p21
Waf1/Cip1 and Bax. The probed membrane was then washed and exposed to radiographic film. cDNA fragments for p21
Waf1/Cip1 , Bax, PIG-3 (21), P53AIP1 (22) and PERP (23) were amplified by RT-PCR, cloned into a TA cloning vector, purified from the vector and then used as probes for Northern blot assay. PCR primers were as follows: p21
Waf1/Cip1 forward, gttccttgtggagccggagc; reverse, ggtacaa gacagtgacaggtc; Bax forward, tttgcttcagggtttcatcc; reverse, ccatcttcttccagatggtga; PIG-3 forward, aaattcaccaaaggtgctgg; reverse, gttcttgttggcctccatgt; PERP forward, catcgccttcga catcatc; reverse, tcaaagtcgcctggagaaac; p53AIP1 forward, gaatggcagggctcagacac; reverse, tcagatttggggatacagaagga.
Luciferase assay. Firefly-luciferase reporter contsructs, pG13 Py-luc, containing 13 copies of a p53 DNA-binding consensus sequence linked to a luciferase reporter gene (gift from Dr B. Vogelstein, Johns Hopkins University), and pMO3, Bax promoter-luciferase construct (gift from Dr M. Oren, Weizmann Institute, Israel) were used to test transcriptional activities of p53. The cells (3x10 6 ) were placed in each well of 6-well plates, and 1 μg of the reporter construct and 20 ng of Renila-luciferase vector pRL-CMV (Promega, Tokyo, Japan) were cotransfected to the cells by a lipofection method (Lipofectamine, Gibco-BRL). After transfection with the reporter construct, the cells were infected with Ad-p53 or Ad-Null at 25 MOI. After incubation with Ad-p53 or AdNull for 1 h, TSA was added to the cultures. After incubation for 24 h, cells were lysed with the use of Passive Lysis buffer (Promega). Then luciferase activities were measured with a Dual-Luciferase TM Reporter Assay System (Promega) according to the manufacturer's instruction.
Western blot analysis. Western blot analysis was performed according to the method described previously (24) . Briefly, samples were electrophoresed under non-reducing conditions on 12% polyacrylamide gels in Tris-glycin running buffer and electrotransferred to a 0.45 μm nitrocellulose membrane. The membrane was then blocked overnight at 4˚C in blocking buffer (5% skim-milk in 1% Tween-phosphate-buffered saline) and probed with first antibodies for 1 h. After being washed, the membrane was incubated with a peroxidaseconjugated goat anti-mouse IgG secondary antibody (Jackson ImmunoResearch, PA, USA) and developed with the use of an ECL detection kit (Amersham, Tokyo, Japan).
Results
Expression of p53 mRNA and protein. Fig. 1A shows the p53 mRNA expression levels in MDA-MB-231 cells after the treatment with p53 gene transfer and/or TSA. Wild-type p53 mRNA expression was clearly induced by the infection with Ad-p53 at 25 MOI with or without TSA. TSA showed no additive effect on the p53 mRNA expression levels. The expression of p21 waf1 mRNA was also induced by the infection with Ad-p53 at 25 MOI. Treatment with TSA only slightly showed an additive effect on the p21 mRNA expression induced by p53 gene transfer alone. Fig. 1B shows the p53 protein levels after the treatment with TSA alone, p53 gene transfer alone and the combination of the two. Likewise, TSA showed no additive effect on the p53 protein expression levels. The reporter gene assay using pG13-Luc, which expresses the luciferase under the control of the p53-responsive elements, showed that p53 gene transfer markedly stimulates the reporter activity and that TSA treatment slightly enhanced the reporter activity (Fig. 1C) .
Cell death following treatment with p53 gene transfer and/or TSA. As shown in Fig. 2A , the combination of TSA and p53 
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induced apoptosis in 39.2%, whereas p53 (25 MOI) alone and TSA (250 nM) alone induced apoptosis in 13.1% and 5% of MDA-MB-231 cells, respectively. In order to confirm the results, we also examined the apoptosis with the use of a TUNEL staining method. Whereas a few MDA-MB-231 cells were positive for TUNEL staining when treated with TSA alone or p53 alone, a more number of the cells were positive for the staining after the treatment with the combination of TSA and p53 (Fig. 1B) . We also examined the effects of the combination of TSA and p53 on cell viability by MTS assay. As shown in Fig. 1C , the cell death in MDA-MB-231 was induced synergistically by the combination of TSA and p53 gene transfer.
Caspase-3 activity following treatment with p53 and/or TSA. Next, we examined the effect of the combination of TSA and p53 on caspase activation. Fig. 3A shows caspase-3 activities after the treatment with p53 and/or TSA. p53 alone at up to 100 MOI or TSA alone (250 and 500 nM) slightly activated caspase-3, whereas p53 in combination with TSA activated caspase-3 synergistically in a dose-dependent manner. Reversely the caspase-3 activation and apoptosis induced by the combination of p53 and TSA was inhibited by a protease-inhibitor, Z-VAD, in a dose-dependent manner ( Fig. 3B and C) .
Expression of apoptosis-related genes.
Since it has been reported that Bax is involved in p53-induced apoptosis, we next examined whether Bax gene expression is modulated by the combination treatment of p53 gene transfer and TSA. Fig. 4A shows that the Bax mRNA expression was induced by the infection with Ad-p53 at 25 MOI. However, TSA did not enhance the Bax mRNA expression induced by p53 alone. Reporter gene assay also demonstrated that TSA did (Fig. 4B ). Next we examined expressions of other p53-dependent apoptosis-related genes. Expression levels of these genes examined in this study were not enhanced by TSA (Fig. 4C) .
Mitochondrial membrane potential. Fig. 5A shows the mitochondrial membrane potential after the treatment with p53 gene transfer and/or TSA. While TSA alone or p53 gene transfer alone slightly decreased the mitochondrial membrane potential, the combination of TSA and p53 gene transfer synergistically decreased it. As shown in Fig. 5B , TSA alone decreased the mitochondrial membrane potential in a dose-dependent manner in the cells without wild-type p53, suggesting that TSA decreased the mitochondrial membrane potential in a p53-independent manner.
Discussion
Trichostatin A (TSA) has been known to inhibit histone deacetylase activity (10) . As histone acetylation mediates transcriptional activation by facilitating the binding of transcription factors to nucleosomal DNA (15) , it is reasonable to hypothesize that TSA could enhance p53-dependent transcription of down-stream genes, such as p21 Waf1/Cip1 and Bax, through the enhanced binding of p53 to its binding sites in the promoter region and then induce apoptosis and cell cycle arrest more efficiently in the combination with p53 gene transfer than in p53 gene transfer alone. In this study, we demonstrated that TSA, which itself induce low levels of apoptosis at the concentrations up to 500 nM, synergistically induced apoptosis in MDA-MD-231 cells, in combination with p53 gene transfer.
The mechanisms by which p53 gene transfer induces apoptosis in the cells with mutated p53 gene are yet to be determined. A number of studies provided evidence that transcriptional activation of p53 was required for apoptosis in some experimental systems (23, (25) (26) (27) (28) . Furthermore, it has been reported that some histone deacethylase inhibitors enhanced the transcriptional activity of p53, resulting in the induction of apoptosis (16) . In contrast, there is also strong evidence that p53 can induce apoptosis independently of its transcriptional function (28) (29) (30) (31) (32) . We clearly demonstrated that p53 gene transfer by itself induced the transcription of p21
Waf1/Cip1 and Bax, which were reported to be induced by p53 (33), but did not induce comparable levels of apoptosis with the expression levels of p21 and Bax. This suggested that the transcription of Bax was not sufficient for the induction of apoptosis in some cancer cells. Furthermore, we demonstrated that the combination of p53 gene transfer and TSA reduced mitochondrial membrane potential and the activation of caspase-3. These results suggest that TSA and p53 gene transfer synergistically induced apoptosis at least partially through the synergistic reduction of mitochondrial membrane potential and the activation of caspase cascade. As TSA alone decreased the mitochondrial membrane potential in a p53-independent manner in our study, TSA showed the synergistic effect partially through the direct reduction of mitochondrial membrane potential. A similar result has been reported. Medina et al reported that TSA induced caspase-3 activation and apoptosis of Jurkat and colorectal carcinoma cell lines synergistically through a mitochondrial/cytochrome c-dependent pathway (13) . Moreover, it has been reported that p53 translocated to mitochondria decreased mitochondrial membrane potential and activated caspase-3, which is consistent with our results (34) (35) (36) . Further investigation is required for understanding the mechanisms by which TSA and p53 gene transfer synergistically induced apoptosis in a variety of cancer cell lines; however, it seems likely that death signals triggered by the combination of TSA and p53 gene transfer converged at the mitochondrial membrane potential. It has been demonstrated that histone deacetylate inhibitors induced PIC-3 and Noxa through the acetylation of p53 (37) . The difference between our results and theirs cannot be explained presently. We now speculate that the difference might derive from the differences of the cell lines used in the study.
There are several advantages in the combination therapy with histone deacetylase inhibitors and p53 gene transfer for cancers. Our results suggest that the combination induces apoptosis of the cancer cells located even distantly from the injection sites of Ad-p53 and thus receiving low copy numbers of Ad-p53. Furthermore, the combination of p53 gene transfer and histone deacetylase inhibitors may even induce apoptosis of the cancer cells that are resistant to apoptosis induction by p53 gene transfer alone. 
